Galimedix Therapeutics is an ophthalmic pharmaceutical company that is dedicated to developing innovative treatments for neurodegenerative diseases. Based in the United States, Galimedix is currently in the Phase 2 clinical stage and focuses on transformative treatments that target toxic oligomers of amyloid beta (Aβ), which is the common cause for diseases like Alzheimer’s, glaucoma, and dry age-related macular degeneration (dry AMD). Their initial focus is on developing an eye drop treatment for dry AMD and glaucoma, two leading causes of blindness.

By utilizing eye drops, Galimedix aims to provide a more convenient and safe administration method for long-term treatments. The company has an exclusive global license from Tel Aviv University, which includes valuable data from Merz Pharmaceuticals, a Germany-based company. Galimedix's team comprises top neuropharmaceutical experts who developed the successful Alzheimer’s drug Namenda.

They have conducted pharmacokinetic studies that demonstrate the efficacy of their eye drops by reaching drug concentrations more than 30 times the estimated target affinity in the retina. With compelling efficacy data from animal models, support from experts, and a rich history of development, Galimedix is committed to revolutionizing the treatment of neurodegenerative diseases